Pharmacokinetics of oral fumarates in healthy subjects

British Journal of Clinical Pharmacology

Volumn 58, Issue 4, 2004, Pages 429-432

  Litjens, Nicolle H R ^a   Burggraaf, Jacobus ^b   Van Strijen, Elisabeth ^a   Van Gulpen, Co ^a   Mattie, Herman ^a   Schoemaker, Rik C ^b   Van Dissel, Jaap T ^a   Thio, H Bing ^c   Nibbering, Peter H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Fumarates; High performance liquid chromatography; Monomethylfumarate; Pharmacokinetics; Psoriasis

Indexed keywords

DRUG METABOLITE; FUMARAAT; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEAL; NORMAL HUMAN; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; ANTICARCINOGENIC AGENTS; FEMALE; FUMARATES; HUMANS; MALE; TABLETS;

EID: 4744366092     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02145.x     Document Type: Article

References (16)

1. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42: 617-21.
2. Davison SC, Bunker CB, Basarab T. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002; 147: 831-2.
3. Koo J, Lee J. Cyclosporine: what clinicians need to know. Dermatol Clin 1995; 13: 897-907.
4. Griffiths CE, Clark CM, Chalmers RJ, Li Wan PA, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000; 4: 1-125.
5. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204.
6. Schweckendiek W. Heilung von Psoriasis vulgaris. Med Monatschr 1959; 13: 103-4.
7. Altmeyer PJ, Matthes U, Pawlak F et al. Antipsoriatic effect of fumaric acid derivates; results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30: 977-81.
8. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumarates: results of a prospective multicentre study. German Multicentre Study. Br J Dermatol 1998; 138: 456-60.
9. Nugteren-Huying WM, van der Schroeff JG, Hermans J, Suurmond D. Fumaric acid therapy for psoriasis: a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 1990; 22: 311-12.
10. Thio HB, van der Schroeff JG, Nugteren-Huying WM, Vermeer BJ. Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venereol 1995; 4: 35-40.
11. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumarates in severe psoriasis. Br J Dermatol 2003; 149: 363-9.
12. Litjens NHR, Nibbering PH, Barrais AJ et al. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type-1 cytokines. Br J Dermatol 2003; 148: 444-51.
13. Mrowietz U, Christophers E, Altmeyer P. Treatment of severe psoriasis with fumarates: scientific background and guidelines for therapeutic use. The German Fumaric Acid Ester Consensus Conference. Br J Dermatol 1999; 141: 424-9.
14. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumarates. Biopharm Drug Dispos 2003; 24: 259-73.
15. Kolbach DN, Nieboer C. Fumaric acid therapy in psoriasis: results and side effects of 2 years of treatment. J Am Acad Dermatol 1992; 27: 769-71.
16. Nieboer C, de Hoop D, Langendijk PN, Van Loenen AC, Gubbels J. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990; 181: 33-7.